Changes in PD-1 expression on T lymphocyte subsets and related immune indicators before and after definitive chemoradiotherapy for esophageal squamous cell carcinoma
- PMID: 39713872
- PMCID: PMC11703528
- DOI: 10.1080/07853890.2024.2445190
Changes in PD-1 expression on T lymphocyte subsets and related immune indicators before and after definitive chemoradiotherapy for esophageal squamous cell carcinoma
Abstract
Objective: This study aimed to observe the dynamic changes in the expression of T lymphocytes, natural killer (NK) cells, and PD-1 in patients with first-diagnosed esophageal squamous cell carcinoma (ESCC) before and after chemoradiotherapy (CRT) and evaluate the impact of PD-1 expression in peripheral blood on the short-term outcome of patients with ESCC.
Patients and methods: Seventy-three patients with ESCC who were treated with definitive CRT were enrolled. Before and after CRT, flow cytometry was used to detect thePD-1 expression in the peripheral blood and related immune indicators. Peripheral blood from 10 healthy individuals was used as control.
Results: The percentages of CD3+ (p = 0.018), CD4+ (p < 0.001), and CD8+ T cells (p < 0.001); NK cells (p = 0.009); and the CD4+/CD8+ ratio (p < 0.001), as well as PD-1+CD3+ (p < 0.001), PD-1+CD4+ (p < 0.001), and PD-1+CD8+ (p < 0.001) T cells, before CRT significantly differed from those in the post-CRT group. The percentages of PD-1+CD8+ T cells differed significantly between the radiotherapy alone and CRT groups (p < 0.05). PD-1 expression in CD3+, CD4+, and CD8+ T cells significantly decreased in patients achieving overall response rate (all p < 0.05). Compared with those in the incomplete response group, PD-1+CD8+ T cells significantly decreased in the CR group (p < 0.05).
Conclusion: CRT aggravated immunosuppression and increased PD-1 expression in T lymphocyte subsets in patients with ESCC, possibly related to the radiation field. PD-1 expression in T lymphocyte subsets can predict short-term outcomes in patients and provide a theoretical basis for the sequential application of PD-1 immunosuppressants after radiotherapy and chemotherapy.
Keywords: NK cells; PD-1; T lymphocyte subsets; chemoradiotherapy; esophageal squamous cell carcinoma; immunotherapy.
Plain language summary
Chemoradiotherapy (CRT) reduced the overall immune function of patients with esophageal squamous cell carcinoma (ESCC), and the degree of decline was related to the irradiation area.PD-1 expression in T lymphocytes increased considerably after CRT, suggesting that the sequential application of PD-1 immunosuppressants after radiotherapy and chemotherapy can be beneficial.PD-1 expression on T lymphocytes may serve as a potential indicator for predicting the short-term outcomes of ESCC.
Conflict of interest statement
No potential conflict of interest was reported by the author(s).
Figures




Similar articles
-
Definitive chemoradiotherapy induces T-cell-inflamed tumor microenvironment in unresectable locally advanced esophageal squamous cell carcinoma.J Gastroenterol. 2024 Sep;59(9):798-811. doi: 10.1007/s00535-024-02120-z. Epub 2024 May 31. J Gastroenterol. 2024. PMID: 38819498
-
Effects of chemoradiotherapy on surface PD-L1 expression in esophageal cancer and its implications for immunotherapy.Front Immunol. 2024 Dec 23;15:1509051. doi: 10.3389/fimmu.2024.1509051. eCollection 2024. Front Immunol. 2024. PMID: 39763660 Free PMC article.
-
LAG3 as a marker of immune activation in esophageal squamous carcinoma treated with concurrent chemoradiotherapy.Cancer Immunol Immunother. 2025 May 24;74(7):215. doi: 10.1007/s00262-025-04076-2. Cancer Immunol Immunother. 2025. PMID: 40411616 Free PMC article.
-
Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma.Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):286-294. doi: 10.1016/j.ijrobp.2020.01.020. Epub 2020 Jan 28. Int J Radiat Oncol Biol Phys. 2020. PMID: 32004580
-
TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.BMC Cancer. 2020 Apr 20;20(1):336. doi: 10.1186/s12885-020-06716-5. BMC Cancer. 2020. PMID: 32312286 Free PMC article. Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials